Compare Orchid Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs NATCO PHARMA - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA NATCO PHARMA ORCHID PHARMA/
NATCO PHARMA
 
P/E (TTM) x -121.8 35.3 - View Chart
P/BV x 34.9 5.0 695.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
NATCO PHARMA
Mar-19
ORCHID PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs194849 22.9%   
Low Rs35557 6.3%   
Sales per share (Unadj.) Rs276.5573.8 48.2%  
Earnings per share (Unadj.) Rs-79.2176.0 -45.0%  
Cash flow per share (Unadj.) Rs-43.5198.2 -21.9%  
Dividends per share (Unadj.) Rs06.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs53.9842.7 6.4%  
Shares outstanding (eoy) m70.4536.50 193.0%   
Bonus / Rights / Conversions ESOPBB-  
Price / Sales ratio x0.41.2 33.8%   
Avg P/E ratio x-1.44.0 -36.2%  
P/CF ratio (eoy) x-2.63.5 -74.3%  
Price / Book Value ratio x2.10.8 254.5%  
Dividend payout %03.6 0.0%   
Avg Mkt Cap Rs m8,06725,660 31.4%   
No. of employees `0002.85.0 56.5%   
Total wages/salary Rs m2,5273,559 71.0%   
Avg. sales/employee Rs Th6,956.14,225.3 164.6%   
Avg. wages/employee Rs Th902.5718.0 125.7%   
Avg. net profit/employee Rs Th-1,993.01,295.9 -153.8%   
INCOME DATA
Net Sales Rs m19,47720,945 93.0%  
Other income Rs m4071,302 31.3%   
Total revenues Rs m19,88422,247 89.4%   
Gross profit Rs m1,1037,948 13.9%  
Depreciation Rs m2,519810 311.0%   
Interest Rs m5,227193 2,708.2%   
Profit before tax Rs m-6,2368,247 -75.6%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,823 -6.9%   
Profit after tax Rs m-5,5806,424 -86.9%  
Gross profit margin %5.737.9 14.9%  
Effective tax rate %2.022.1 9.1%   
Net profit margin %-28.730.7 -93.4%  
BALANCE SHEET DATA
Current assets Rs m11,01423,472 46.9%   
Current liabilities Rs m32,0607,287 440.0%   
Net working cap to sales %-108.177.3 -139.8%  
Current ratio x0.33.2 10.7%  
Inventory Days Days9592 102.9%  
Debtors Days Days3488 38.0%  
Net fixed assets Rs m29,44018,648 157.9%   
Share capital Rs m705365 193.0%   
"Free" reserves Rs m2,04334,525 5.9%   
Net worth Rs m3,80030,760 12.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51043,031 108.1%  
Interest coverage x-0.243.7 -0.4%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.5 86.0%   
Return on assets %-0.815.4 -4.9%  
Return on equity %-146.920.9 -703.2%  
Return on capital %-3.727.4 -13.6%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51311,536 65.1%   
Fx outflow Rs m5,6492,939 192.2%   
Net fx Rs m1,8658,597 21.7%   
CASH FLOW
From Operations Rs m1,6826,688 25.1%  
From Investments Rs m-9,860-6,122 161.1%  
From Financial Activity Rs m6,644-509 -1,305.3%  
Net Cashflow Rs m-1,53566 -2,325.8%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 4.6 7.8 58.7%  
FIIs % 3.3 16.6 19.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 26.0 212.7%  
Shareholders   84,811 25,395 334.0%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare ORCHID PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 650 Points, Reclaims 50,000 Mark; Bajaj Finance & IndusInd Bank Top Gainers(09:30 am)

Asian share markets rose in early trade today, shrugging off worries about an increase in regional coronavirus infections and a subdued session on Wall Street.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


May 18, 2021 01:29 PM

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 5-YR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS